Citius Oncology (CTOR) Competitors $1.58 -0.05 (-3.07%) (As of 09/18/2024 ET) Add Compare Share Share Competitors Stock AnalysisChartCompetitorsFinancialsSEC FilingsTrends CTOR vs. DMAQ, WENA, RWOD, NVNI, VSEE, ABVE, BENF, PSIG, MKDW, and SLXNShould you be buying Citius Oncology stock or one of its competitors? The main competitors of Citius Oncology include Deep Medicine Acquisition (DMAQ), ANEW Medical (WENA), Redwoods Acquisition (RWOD), Nvni Group (NVNI), Vsee Health (VSEE), Above Food Ingredients (ABVE), Beneficient (BENF), PSI Group (PSIG), MKDWELL Tech (MKDW), and Silexion Therapeutics (SLXN). These companies are all part of the "holding & other investment offices" industry. Citius Oncology vs. Deep Medicine Acquisition ANEW Medical Redwoods Acquisition Nvni Group Vsee Health Above Food Ingredients Beneficient PSI Group MKDWELL Tech Silexion Therapeutics Deep Medicine Acquisition (NASDAQ:DMAQ) and Citius Oncology (NASDAQ:CTOR) are both small-cap unclassified companies, but which is the better investment? We will compare the two companies based on the strength of their analyst recommendations, institutional ownership, earnings, dividends, media sentiment, profitability, risk, community ranking and valuation. Which has more risk and volatility, DMAQ or CTOR? Deep Medicine Acquisition has a beta of 0.02, suggesting that its stock price is 98% less volatile than the S&P 500. Comparatively, Citius Oncology has a beta of -0.09, suggesting that its stock price is 109% less volatile than the S&P 500. Do analysts recommend DMAQ or CTOR? Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Deep Medicine Acquisition 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) N/ACitius Oncology 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) N/A Which has better earnings and valuation, DMAQ or CTOR? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioDeep Medicine AcquisitionN/AN/AN/AN/AN/ACitius OncologyN/AN/AN/AN/AN/A Do institutionals & insiders hold more shares of DMAQ or CTOR? 18.4% of Deep Medicine Acquisition shares are held by institutional investors. 1.7% of Deep Medicine Acquisition shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth. Does the MarketBeat Community believe in DMAQ or CTOR? Deep Medicine Acquisition and Citius Oncology both received 0 outperform votes by MarketBeat users. CompanyUnderperformOutperformDeep Medicine AcquisitionN/AN/ACitius OncologyN/AN/A Is DMAQ or CTOR more profitable? Company Net Margins Return on Equity Return on Assets Deep Medicine AcquisitionN/A N/A N/A Citius Oncology N/A N/A N/A Does the media favor DMAQ or CTOR? In the previous week, Citius Oncology had 1 more articles in the media than Deep Medicine Acquisition. MarketBeat recorded 1 mentions for Citius Oncology and 0 mentions for Deep Medicine Acquisition. Citius Oncology's average media sentiment score of 1.89 beat Deep Medicine Acquisition's score of 0.00 indicating that Citius Oncology is being referred to more favorably in the news media. Company Overall Sentiment Deep Medicine Acquisition Neutral Citius Oncology Very Positive SummaryDeep Medicine Acquisition beats Citius Oncology on 3 of the 5 factors compared between the two stocks. Ad Porter & CompanyWar on Elon Escalates… Elon Musk, the guy slated to become the world’s first trillionaire by 2027, has publicly called for the adoption of this technology for decades. By doing so he has put himself in the crosshairs of an ideological war with the global elites. And yet, while this new technology threatens their wealth and power, it could be transformational for both the U.S. economy and your wealth.Click here to learn how you can benefit from its widespread distribution. Get Citius Oncology News Delivered to You Automatically Sign up to receive the latest news and ratings for CTOR and its competitors with MarketBeat's FREE daily newsletter. Email Address Media Sentiment Over TimeWhat are MarkeBeat Followers?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CTOR vs. The Competition Export to ExcelMetricCitius OncologyHolding Offices IndustryMedical SectorNASDAQ ExchangeMarket Cap$3.78M$408.87M$5.64B$8.25BDividend YieldN/A7.58%4.33%4.08%P/E RatioN/A12.02145.2118.57Price / SalesN/A6.941,614.7073.26Price / CashN/A69.3236.8531.87Price / BookN/A86.354.834.54Net IncomeN/A$28.85M$114.76M$224.04M7 Day Performance-5.33%0.92%4.28%5.48%1 Month Performance-20.00%-0.83%9.53%8.73%1 Year PerformanceN/A-2.66%29.01%12.32% Citius Oncology Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)DMAQDeep Medicine Acquisition0 of 5 stars0.00 / 5 stars$2.96-64.7%N/A-89.2%$12.90MN/A0.0093Gap UpHigh Trading VolumeWENAANEW Medical0 of 5 stars0.00 / 5 stars$0.73-1.4%N/AN/A$12.58MN/A0.00N/ANews CoveragePositive NewsRWODRedwoods Acquisition0 of 5 stars0.00 / 5 stars$2.34-60.3%N/A-93.2%$12.09MN/A0.00N/AGap DownNVNINvni Group3.485 of 5 stars3.49 / 5 stars$1.00-4.8%$5.00+400.0%N/A$10.05MN/A0.00N/AUpcoming EarningsPositive NewsVSEEVsee Health0 of 5 stars0.00 / 5 stars$1.57-1.9%N/AN/A$5.66M$6.38M0.00N/AGap UpABVEAbove Food Ingredients0 of 5 stars0.00 / 5 stars$0.63+0.2%N/AN/A$5.07M$368.42M0.00N/APositive NewsBENFBeneficient1.4179 of 5 stars1.42 / 5 stars$1.23-3.1%N/A-99.4%$4.43M$-86,119,000.000.0080Gap DownPSIGPSI Group0 of 5 stars0.00 / 5 stars$0.97-0.5%N/AN/A$3.50MN/A0.00N/AMKDWMKDWELL Tech0 of 5 stars0.00 / 5 stars$0.88-4.0%N/AN/A$3.36M$3.67M0.00N/APositive NewsGap DownSLXNSilexion Therapeutics0 of 5 stars0.00 / 5 stars$0.99-2.0%N/AN/A$3.33MN/A0.00N/APositive News Related Companies and Tools Related Companies: Deep Medicine Acquisition Competitors ANEW Medical Competitors Redwoods Acquisition Competitors Nvni Group Competitors Vsee Health Competitors Above Food Ingredients Competitors Beneficient Competitors PSI Group Competitors MKDWELL Tech Competitors Silexion Therapeutics Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:CTOR) was last updated on 9/18/2024 by MarketBeat.com Staff From Our PartnersChina Stockpiling Gold “Like No Tomorrow”For 18 consecutive months, China’s central bank has increased its gold reserve. The country, with a populat...True Gold Republic | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredThis diversified cannabis pioneer could make huge moves soonThe cannabis industry seems deeply saturated, so how do you know where to best invest your money? Let’s start ...Greenlane | SponsoredUnlock the Secret to Easy Wins with Iron CondorsDiscover the power of Iron Condor trades – a low-risk, high-reward strategy that allows you to profit consiste...Netpicks | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredSell NVDA Now?Guess who's selling NVDA next The most successful hedge fund in history quietly sold 500,000 shares. Here's...Chaikin Analytics | Sponsored625,000% GainThe recent crypto correction has shaken many investors, causing panic and uncertainty. But while others are fr...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Citius Oncology, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Citius Oncology With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
